InsidersTradesSigma
ZYNEX INC Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the ZYNEX INC share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, ZYNEX INC has logged 179 public disclosures. The latest transaction was reported on 27 March 2026 (Disposition). Among the most active insiders: MOORHEAD DANIEL J. The full history is accessible without an account.
179
Insider Decl.
n/a
Thresholds
€53,822
1 ops.
Buy Volume
€13m
21 ops.
Sell Volume
34Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 27 March 2026
Declarations179 total
12,499 shares0Common Stock (Restricted Stock Award)SEC:0001745117-26-000002:0
12,499 shares0Common Stock (Restricted Stock Award)SEC:0001566240-26-000002:0
80,001 shares0Common StockSEC:0001162525-26-000002:0
7,500 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-020510:0
3,982 shares@ US$2.130.8% of flowCommon StockSEC:0001415889-25-016070:0
10,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-013481:0
10,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-013482:0
10,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-013480:0
7,500 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-011547:0
1,700,000 shares@ US$2.90531.7% of flowCommon StockSEC:0001104659-25-024556:0
10,000 shares@ US$7.156.8% of flowCommon StockSEC:0001415889-25-007098:0
10,000 shares@ US$7.687.4% of flowCommon StockSEC:0001415889-25-002804:0
7,500 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-002296:0
10,000 shares@ US$7.887.5% of flowCommon StockSEC:0001415889-25-000658:0
5,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-24-028557:0
10,000 shares@ US$8.087.6% of flowCommon StockSEC:0001415889-24-028194:0
2,000 shares@ US$8.090.1% of flowCommon StockSEC:0001415889-24-027128:0
2,000 shares@ US$9.170.1% of flowCommon StockSEC:0001415889-24-026751:0
2,000 shares@ US$8.670.1% of flowCommon StockSEC:0001415889-24-026282:0
10,000 shares@ US$8.597.8% of flowCommon StockSEC:0001415889-24-026049:0
2,000 shares@ US$8.920.1% of flowCommon StockSEC:0001415889-24-025931:0
6,912 shares0Common Stock (Restricted Stock Award)SEC:0001415889-24-025706:0
6,912 shares0Common Stock (Restricted Stock Award)SEC:0001415889-24-025705:0
5,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-24-025704:0
5,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-24-022975:0
25 of 179 declarations
关于 ZYNEX INC
Zynex Inc.（股票代码：ZYXI）是一家美国医疗设备公司，已在美国纳斯达克市场上市。该公司总部位于科罗拉多州恩格尔伍德，由Thomas Sandgaard于1996年创立。其核心业务历来专注于电疗和疼痛管理解决方案，主要服务于美国以及更广泛的北美地区的患者和医疗保健提供者。([sec.gov](https://www.sec.gov/Archives/edgar/data/846475/000155837025002717/zyxi-20241231x10k.htm?utm_source=openai)) 该公司的主要运营业务是Zynex Medical，其设计、制造和销售用于治疗急性和慢性疼痛以及通过电刺激激活和康复肌肉的设备。其商业产品组合包括TENS、IFC和NMES系统等设备，这些设备与经常性耗材一起销售或租赁，以及包括颈椎和腰椎牵引、护膝、腕部支撑和冷热疗法产品在内的补充康复产品。设备销售和经常性供应收入的这种组合是该模式的一个重要特征，因为安装基础的增长可以支持后续的耗材需求。([sec.gov](https://www.sec.gov/Archives/edgar/data/846475/000155837025009557/zyxi-20241231x10ka.htm?utm_source=openai)) Zynex还运营Zynex Monitoring Solutions (ZMS)，这是一个规模较小且更侧重于开发的部门，专注于非侵入性监测技术。SEC文件显示，ZMS开发了一种流体监测系统，该系统在美国获得了初步的FDA批准，该公司还在欧洲寻求监管途径。最近，该公司披露了该业务的战略调整，包括ZMS的大规模裁员以实现成本节约，这强调了监测仍然是一个期权价值资产，而不是一个成熟的盈利驱动因素。([sec.gov](https://www.sec.gov/Archives/edgar/data/846475/000155837025002717/zyxi-20241231x10k.htm?utm_source=openai)) 从竞争角度来看，Zynex是非侵入性疼痛治疗和康复领域的利基参与者，而不是一个广泛多元化的医疗技术平台。其定位取决于医生关系、销售团队执行力、报销渠道以及其家用疗法产品的广度。该公司表示，其绝大部分收入来自北美，因此其地理足迹仍然集中且在国际上相对有限。([sec.gov](https://www.sec.gov/Archives/edgar/data/846475/000155837025009557/zyxi-20241231x10ka.htm?utm_source=openai)) 最近的发展对投资者而言具有高度实质性。2025年期间，Zynex报告了订单趋势疲软、供应收入下降、销售团队缩减以及临时Tricare报销问题带来的压力。该公司还披露了ZMS的重组。最重要的是，在2025年12月15日，Zynex及其某些子公司在美国提交了自愿的第11章破产申请，此后纳斯达克暂停了普通股的交易，股票于2025年12月下旬被移至Pink Limited Market。对于股权投资者而言，这意味着Zynex应被视为一个面临重大运营、报销和资产负债表风险的困境重组案例。([sec.gov](https://www.sec.gov/Archives/edgar/data/846475/000110465925121390/zyxi-20251215x8k.htm?utm_source=openai))
